SynteractHCR to Share Insights on the New EU Clinical Trials Regulation at 2015 Partnerships in Clinical Trials Europe
Full-service contract research organization (CRO) SynteractHCR will share its Phase I-IV clinical trials expertise as well as its regulatory affairs knowledge at Partnerships in Clinical Trials Europe (PCT Europe), to be held Nov. 17-19 in Hamburg, Germany. The CRO’s global clinical trial experts will be at booth #503 to discuss their services that support the drug development programs of small to mid-sized biopharma companies.
Dr. Martine Dehlinger-Kremer , global vice president of medical and regulatory affairs, will present “The New EU Clinical Trials Regulation: What Does it Change and What Will the Impact Be to Drug Development in the EU?” on Thursday, Nov. 19th , at 11:50 a.m. Her presentation will address the rationale behind changing the previous clinical trials directive as well as the following:
- Timeline for the new EU CT Regulation to go into effect
- Core components and country-specific aspects of the Regulation
- Differences between the EMA’s and FDA’s expectations
- The advantages of the New EU CT Regulation and the impact that this will have on sponsors
Named one of the 2015 PharmaVOICE 100 Most Inspiring People in Life Sciences , Dr. Dehlinger-Kremer is a leading expert in regulatory affairs. As an advocate for harmonization among regulatory bodies in different countries, she hosted a webinar and has been featured in multiple media outlets on the topic of the New EU Clinical Trials Regulation.
Attendees who would like to schedule an appointment with SynteractHCR at PCT Europe may contact Sebastien Duval, vice president business development Europe, at +33 6 01 61 21 81. See SynteractHCR's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during the PCT Europe conference.
SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. SynteractHCR has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision ” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.
SynteractHCR will exhibit at booth 503 and present on the new EU Clinical Trials Regulation at PCT Europe.
Amanda Whitlock, 760-230-2424
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CELLTRION15.12.2017 23:15 | pressemeddelelse
Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar
TAKEDA15.12.2017 13:36 | pressemeddelelse
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
TWISPAY15.12.2017 13:23 | pressemeddelelse
Bitcoin Romania and Twispay Announce Integration Partnership Providing Users with the Ability to Purchase Bitcoin with Bank Cards
PEACE-FORUM15.12.2017 12:40 | pressemeddelelse
Upon Conclusion of the Fourth Annual Forum for Promoting Peace in Muslim Societies, Scholars and Intellectuals Visit the Louvre Abu Dhabi Museum
CA-KENNEDY-WILSON15.12.2017 12:02 | pressemeddelelse
Kennedy Wilson Acquires 124-Unit Northbank Apartments in Dublin, Ireland for €45 Million
NV-NAC-FOUNDATION15.12.2017 10:02 | pressemeddelelse
AML BitCoin Enters Phase II of ICO
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum